Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link

Disclaimer: Early release articles are not considered as final versions. Any changes will be reflected in the online version in the month the article is officially released.

Volume 31, Number 12—December 2025

Research Letter

Macrolide-Resistant Mycoplasma pneumoniae in Children, Ohio, USA

Huanyu WangComments to Author , Tori Embry, Kathy Everhart, Morgan Szekely, Jeanette Taveras, Sophonie J. Oyeniran, and Amy L. Leber
Author affiliation: Nationwide Children’s Hospital, Columbus, Ohio, USA (H. Wang, T. Embry, K. Everhart, M. Szekely, J. Taveras, S.J. Oyeniran, A.L. Leber); The Ohio State University, Columbus (H. Wang, J. Taveras, S.J. Oyeniran, A.L. Leber)

Main Article

Table

Mycoplasma pneumoniae testing volume, number of positive tests, sequencing volume, resistance detection, and azithromycin prescriptions, by month, Ohio, USA, September 2023–May 2025*

Month Total cohort
Urgent care center cohort
No. samples tested No. (%) positive No. (%) sequenced No. (%) resistant No. samples tested No. (%) positive No. (%) sequenced No. (%) resistant Azithromycin prescription rate†
2023
Sep 818 5 (0.6) 0 NA 38 0 0 NA 4
Oct 1,001 29 (2.9) 0 NA 55 6 (10.9) 0 NA 6
Nov 1,348 59 (4.4) 0 NA 102 7 (6.9) 0 NA 8
Dec
1,697
62(3.7)
0
NA

160
13 (8.1)
0
NA
9
2024
Jan 1,388 57 (4.1) 6 (10.5) 0 79 13 (16.5) 5 (38.5) 0 6
Feb 1,303 29 (2.3) 6 (20.7) 0 76 4 (5.3) 2 (50.0) 0 5
Mar 1,085 45 (4.2) 1 (2.2) 0 62 12 (19.4) 1 (8.3) 0 5
Apr 965 56 (5.8) 27 (48.2) 0 73 14 (19.2) 10 (71.4) 0 6
May 1,045 106 (10.1) 47 (44.3) 0 130 36 (27.7) 21 (58.3) 0 8
Jun 1,020 266 (28.1) 145 (54.1) 1 (0.7) 251 126 (50.2) 82 (65.1) 1 (1.2) 25
Jul 1,318 407 (30.9) 226 (55.5) 2 (0.9) 396 194 (48.7) 124 (64.3) 2 (1.6) 35
Aug 2,009 642 (32.0) 285 (44.4) 10 (3.9) 761 343 (45.1) 180 (52.5) 4 (2.2) 51
Sep 3,067 860 (28.0) 252 (29.3) 11 (4.4) 1,253 479 (38.2) 133 (27.8) 3 (3.0) 69
Oct 5,657 1,831 (32.4) 299 (16.3) 26 (8.7) 2,084 826 (39.6) 108 (13.1) 6 (5.6) 109
Nov 6,943 1,649 (23.8) 276 (16.7) 13 (4.7) 2,322 693 (29.8) 117 (16.9) 3 (2.6) 131
Dec
6,210
1,288 (20.7)
270 (21.0)
17 (6.3)

1,976
572 (29.0)
120 (21.0)
6 (5.0)
109
2025
Jan 2,779 388 (14.0) 121 (31.2) 8 (6.6) 587 146 (24.9) 56 (38.4) 2 (3.5) 37
Feb 2,032 118 (5.8) 27 (22.9) 2 (7.4) 300 36 (12.0) 3 (8.3) 1 (33.3) 13
Mar 1,452 38 (2.6) 14 (36.8) 0 174 20 (11.5) 9 (45.0) 0 6
Apr 1,257 26 (2.1) 8 (30.8) 0 132 2 (1.5) 2 (100) 0 6
May
926
8 (0.9)
4 (50.0)
0

131
4 (3.1)
2 (50.0)
0
7
Total 45,320 7,969 (17.6) 2,014 (25.3) 90 (4.5) 11,142 3,545 (31.8) 975 (27.5) 28 (2.9)

*NA, not available. †Per 1,000 patients.

Main Article

Page created: December 11, 2025
Page updated: December 24, 2025
Page reviewed: December 24, 2025
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external